Health Canada Suspends Sales Of Antipsychotic Thioridazine
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency decision to withdraw the drug answers concerns about cardiovascular risk; thioridazine to remain on U.S. market with existing “black box” warning.
You may also be interested in...
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
J&J’s Velcade Is Not Cost-Effective For Multiple Myeloma, U.K.’s NICE Suggests
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.